Literature DB >> 17220530

Lysosomal unesterified cholesterol content correlates with liver cell death in murine Niemann-Pick type C disease.

Eduardo P Beltroy1, Benny Liu, John M Dietschy, Stephen D Turley.   

Abstract

Niemann-Pick type C (NPC) disease is a multisystem disorder resulting from mutations in the NPC1 gene that encodes a protein involved in intracellular cholesterol trafficking. Significant liver dysfunction is frequently seen in patients with this disease. The current studies used npc1 mutant mice to investigate the association between liver dysfunction and unesterified cholesterol accumulation, a hallmark of NPC disease. Data from 92 npc1(-/-) mice (age range, 9-56 days) revealed a significant positive correlation between the plasma activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and whole liver cholesterol content. In 56 day old npc1(-/-) mice that had been fed from 35 days of age a rodent diet or the same diet containing either cholesterol (1.0%, w/w) or ezetimibe (a sterol absorption inhibitor; 0.0125%, w/w), whole liver cholesterol content averaged 33.5 +/- 1.1, 87.9 +/- 1.7, and 20.8 +/- 0.9 mg, respectively. Again, plasma ALT and AST activities were positively correlated with hepatic cholesterol content. In contrast, plasma transaminase levels remained in the normal range in npc1(+/+) mice, in which hepatic esterified cholesterol content had been increased by 72-fold by feeding a high-cholesterol, high-fat diet. These studies suggest that the late endosomal/lysosomal content of unesterified cholesterol correlates with cell damage in NPC disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220530     DOI: 10.1194/jlr.M600488-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  38 in total

1.  Quantitative role of LAL, NPC2, and NPC1 in lysosomal cholesterol processing defined by genetic and pharmacological manipulations.

Authors:  Charina M Ramirez; Benny Liu; Amal Aqul; Anna M Taylor; Joyce J Repa; Stephen D Turley; John M Dietschy
Journal:  J Lipid Res       Date:  2011-02-02       Impact factor: 5.922

2.  Unraveling the sterol-trafficking defect in Niemann-Pick C disease.

Authors:  Stephen L Sturley; Marc C Patterson; Peter Pentchev
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

3.  Cyclodextrin mediates rapid changes in lipid balance in Npc1-/- mice without carrying cholesterol through the bloodstream.

Authors:  Anna M Taylor; Bing Liu; Yelenis Mari; Benny Liu; Joyce J Repa
Journal:  J Lipid Res       Date:  2012-08-14       Impact factor: 5.922

4.  Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse.

Authors:  Benny Liu; Stephen D Turley; Dennis K Burns; Anna M Miller; Joyce J Repa; John M Dietschy
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

Review 5.  Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.

Authors:  Paul Helquist; Frederick R Maxfield; Norbert L Wiech; Olaf Wiest
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

6.  GM2/GD2 and GM3 gangliosides have no effect on cellular cholesterol pools or turnover in normal or NPC1 mice.

Authors:  Hao Li; Stephen D Turley; Benny Liu; Joyce J Repa; John M Dietschy
Journal:  J Lipid Res       Date:  2008-04-30       Impact factor: 5.922

7.  TNF-{alpha} plays a role in hepatocyte apoptosis in Niemann-Pick type C liver disease.

Authors:  Victoria M Rimkunas; Mark J Graham; Rosanne M Crooke; Laura Liscum
Journal:  J Lipid Res       Date:  2008-09-24       Impact factor: 5.922

8.  Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid.

Authors:  Benny Liu; Charina M Ramirez; Anna M Miller; Joyce J Repa; Stephen D Turley; John M Dietschy
Journal:  J Lipid Res       Date:  2009-11-18       Impact factor: 5.922

9.  Development of a Rab9 transgenic mouse and its ability to increase the lifespan of a murine model of Niemann-Pick type C disease.

Authors:  Tatiana Kaptzan; Sally A West; Eileen L Holicky; Christine L Wheatley; David L Marks; Tengke Wang; Kyle B Peake; Jean Vance; Steven U Walkley; Richard E Pagano
Journal:  Am J Pathol       Date:  2008-12-04       Impact factor: 4.307

10.  Evaluation of an anti-tumor necrosis factor therapeutic in a mouse model of Niemann-Pick C liver disease.

Authors:  Melanie Vincent; Naomi L Sayre; Mark J Graham; Rosanne M Crooke; David J Shealy; Laura Liscum
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.